We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$355M
AUM Growth
-$16.8M
(-4.5%)
Cap. Flow
-$19.2M
Cap. Flow
% of AUM
-5.4%
Top 10 Holdings %
Top 10 Hldgs %
50.26%
Holding
91
New
4
Increased
16
Reduced
25
Closed
11
Top Buys
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$9.25M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$4.36M |
| 3 |
Biohaven
BHVN
|
+$3.33M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$3.13M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$2.14M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$16.6M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$5.82M |
| 3 |
Adicet Bio
ACET
|
+$4.74M |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$4.65M |
| 5 |
ETNB
89bio
ETNB
|
+$2.98M |
Sector Composition
| 1 | Healthcare | 81.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| $47M | 13.23% |
566,000
| – | – |
|
2
Stereotaxis
STXS
$160M
| $28.3M | 7.98% |
13,680,554
| – | – |
|
3
Ascendis Pharma A/S
ASND
$17.5B
| $15.9M | 4.48% |
130,212
-5,500
| -4% | -$639K |
|
|
KRTX
4
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14.2M | 3.99% |
72,027
+43,141
| +149% | +$9.25M |
|
5
iShares Biotechnology ETF
IBB
$9.23B
| $13.5M | 3.79% |
102,500
| – | – |
|
|
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $13M | 3.65% |
605,975
+204,499
| +51% | +$4.36M |
|
7
Xenon Pharmaceuticals
XENE
$6.55B
| $12.5M | 3.51% |
316,092
-59,131
| -16% | -$2.15M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $11.4M | 3.22% |
261,235
| – | – |
|
9
Revolution Medicines
RVMD
$39.3B
| $11.4M | 3.21% |
477,785
-2,000
| -0.4% | -$42.5K |
|
|
10
Syndax Pharmaceuticals
SNDX
$2.08B
| $11.4M | 3.2% |
447,073
+91,586
| +26% | +$2.14M |
|
11
Neurocrine Biosciences
NBIX
$17.2B
| $8.73M | 2.46% |
73,121
-7,034
| -9% | -$824K |
|
12
IDEAYA Biosciences
IDYA
$3.55B
| $8.51M | 2.4% |
468,358
-70,203
| -13% | -$1.18M |
|
13
Cytokinetics
CYTK
$11.2B
| $8.43M | 2.37% |
183,995
| – | – |
|
14
DexCom
DXCM
$28.4B
| $7.65M | 2.15% |
67,552
-5,000
| -7% | -$549K |
|
|
SAGE
15
DELISTED
Sage Therapeutics
SAGE
| $6.88M | 1.94% |
180,306
| – | – |
|
16
Edgewise Therapeutics
EWTX
$4.36B
| $6.86M | 1.93% |
766,843
-14,269
| -2% | -$134K |
|
17
Nurix Therapeutics
NRIX
$2.46B
| $6.22M | 1.75% |
566,695
| – | – |
|
|
18
Adicet Bio
ACET
$81.3M
| $5.65M | 1.59% |
39,472
-19,013
| -33% | -$4.74M |
|
19
Fate Therapeutics
FATE
$349M
| $5.56M | 1.57% |
550,940
+11,000
| +2% | +$207K |
|
|
20
Biohaven
BHVN
$2.25B
| $5.46M | 1.54% |
393,113
+236,017
| +150% | +$3.33M |
|
|
MORF
21
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.23M | 1.47% |
195,467
| – | – |
|
22
Alector
ALEC
$167M
| $4.91M | 1.38% |
532,438
| – | – |
|
23
Viking Therapeutics
VKTX
$4.44B
| $4.9M | 1.38% |
521,553
-30,847
| -6% | -$138K |
|
|
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
| $4.31M | 1.22% |
83,446
+17,500
| +27% | +$928K |
|
|
MRUS
25
DELISTED
Merus
MRUS
| $4.18M | 1.18% |
269,893
-7,000
| -3% | -$123K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML